ReviewEJNMMI radiopharmacy and chemistry2024
Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape.
Review in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Linking In Vivo Imaging to Therapeutic Outcome withInternational journal of molecular sciences · 2026Review
- Radiolabelled ZnO, Iron Oxide-Based, and Gold Nanoparticles for Cancer Therapy: Synthesis, Surface Engineering, and Radiolabelling Strategies.International journal of molecular sciences · 2026Review
- Ultrasmall AuExploration (Beijing, China) · 2026Article
- Enhancing the Safety of Nanoparticles in Medicine: Highlights of Progress and Critical Objectives.International journal of nanomedicine · 2026Review
- Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer.Small science · 2025Review
- Auger electron-emitting EGFR-targeted and non-targeted [EJNMMI radiopharmacy and chemistry · 2025Article
- Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications.Pharmaceutics · 2025Review
- Approach to Chelating Radioactivity using Carbon Dots for Positron Emission Tomography Imaging.ACS applied materials & interfaces · 2025Article
- Review
- Leveraging Immunological Properties of Nucleic Acid Nanoparticles to Improve Cancer Therapy.RNA nanomed · 2025Article
- Therapeutic Approaches with Iron Oxide Nanoparticles to Induce Ferroptosis and Overcome Radioresistance in Cancers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Recent Advances in Metal Oxide and Phosphate Nanomaterials Radiolabeling with Medicinal Nuclides.ACS omega · 2024Review
- Palladium-103 (Theranostics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundRadiation nanomedicines are nanoparticles labeled with radionuclides that emit α- or β-particles or Auger electrons for cancer treatment. We describe here our 15 years scientific journey studying locally-administered radiation nanomedicines for cancer treatment. We further present a view of the radiation nanomedicine landscape by reviewing research reported by other groups. MAIN BODY: Gold nanoparticles were studied initially for radiosensitization of breast cancer to X-radiation therapy. These nanoparticles were labeled with
conclusionsRadiation nanomedicines have shown great promise for treating cancer in preclinical studies. Local intratumoural administration avoids sequestration by the liver and spleen and is most effective for treating tumours, while minimizing normal tissue toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.